Ralliant (NYSE:RAL) Stock Rating Lowered by Wall Street Zen

Ralliant (NYSE:RAL) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

A number of other brokerages have also recently commented on RAL. Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective on the stock. in a research note on Wednesday, May 27th. Evercore assumed coverage on shares of Ralliant in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 target price for the company. TD Cowen increased their price target on shares of Ralliant from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a research report on Friday, July 31st. Finally, Citigroup lifted their price objective on shares of Ralliant from $81.00 to $82.00 and gave the company a “buy” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $75.70.

Ralliant Stock Performance

Shares of RAL stock opened at $72.53 on Tuesday. Ralliant has a 52-week low of $37.27 and a 52-week high of $75.41. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. The stock has a market cap of $8.02 billion, a PE ratio of -6.68, a price-to-earnings-growth ratio of 2.66 and a beta of 1.60. The business has a 50-day simple moving average of $68.18 and a 200-day simple moving average of $55.19.

Ralliant (NYSE:RAL) last posted its earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.63 by $0.05. The firm had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities analysts expect that Ralliant will post 2.87 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Danske Bank A S acquired a new stake in Ralliant in the 4th quarter valued at $25,000. Dunhill Financial LLC purchased a new position in Ralliant during the second quarter valued at $25,000. V Square Quantitative Management LLC purchased a new position in Ralliant during the fourth quarter valued at $26,000. Allworth Financial LP grew its position in shares of Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares during the period. Finally, Palisade Asset Management LLC acquired a new stake in shares of Ralliant in the third quarter valued at about $26,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.